EGFR and non-small cell lung carcinoma: EGFR-TKIs, well-established EGFR-targeted therapies in non small cell lung cancer (NSCLC) [51], are generally well-tolerated and not associated with the major side effects of chemotherapeutic agents, such as anemia, neutropenia, and thrombocytopenia [52].